## Anna L Zignego

## List of Publications by Citations

Source: https://exaly.com/author-pdf/6488016/anna-l-zignego-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

180<br/>papers7,602<br/>citations50<br/>h-index81<br/>g-index189<br/>ext. papers8,420<br/>ext. citations5.8<br/>avg, IF5.37<br/>L-index

#	Paper	IF	Citations
180	Hepatitis C virus infection in patients with non-Hodgkinß lymphoma. <i>British Journal of Haematology</i> , <b>1994</b> , 88, 392-4	4.5	392
179	Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. <i>Seminars in Arthritis and Rheumatism</i> , <b>2004</b> , 33, 355-74	5.3	365
178	Infection of peripheral mononuclear blood cells by hepatitis C virus. <i>Journal of Hepatology</i> , <b>1992</b> , 15, 382-6	13.4	365
177	A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 843-53		268
176	Cryoglobulins. <i>Journal of Clinical Pathology</i> , <b>2002</b> , 55, 4-13	3.9	243
175	Extrahepatic manifestations of chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46 Suppl 5, S165-73	3.3	186
174	Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39, 2-17	3.3	183
173	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 444-54	13.6	165
172	Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. <i>Annals of Internal Medicine</i> , <b>2002</b> , 137, 571-80	8	145
171	Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. <i>Hepatology</i> , <b>2016</b> , 64, 1473-1482	11.2	138
170	T(14;18) translocation in chronic hepatitis C virus infection. <i>Hepatology</i> , <b>2000</b> , 31, 474-9	11.2	136
169	Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. <i>Autoimmunity Reviews</i> , <b>2011</b> , 11, 48-55	13.6	135
168	Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. <i>Annals of Internal Medicine</i> , <b>1996</b> , 124, 31-4	8	126
167	Extrahepatic manifestations of HCV infection: facts and controversies. <i>Journal of Hepatology</i> , <b>1999</b> , 31, 369-76	13.4	119
166	Hepatitis C virus RNA localization in human carotid plaques. <i>Journal of Clinical Virology</i> , <b>2010</b> , 47, 72-5	14.5	114
165	Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. <i>Hepatology</i> , <b>2015</b> , 61, 1145-53	11.2	98
164	Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. <i>Blood</i> , <b>2010</b> , 116, 335-42	2.2	97

163	Preliminary classification criteria for the cryoglobulinaemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1183-90	2.4	97
162	Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkinß lymphoma, and cancer. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 327-43	3.4	91
161	Hepatitis C virus-related lymphoproliferative disorders: an overview. <i>World Journal of Gastroenterology</i> , <b>2007</b> , 13, 2467-78	5.6	87
160	Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. <i>Hepatology</i> , <b>1998</b> , 28, 211-8	11.2	85
159	Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkinß lymphoma: evidence for a pathogenetic role. <i>Archives of Virology</i> , <b>1997</b> , 142, 545-55	2.6	83
158	Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. <i>Annals of Internal Medicine</i> , <b>1998</b> , 129, 294-8	8	83
157	HCV-related autoimmune and neoplastic disorders: the HCV syndrome. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39 Suppl 1, S13-21	3.3	82
156	Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. <i>Blood</i> , <b>2003</b> , 102, 1196-201	2.2	79
155	Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. <i>Lupus</i> , <b>1998</b> , 7, 275-9	2.6	78
154	Cryoglobulinaemia. <i>Nature Reviews Disease Primers</i> , <b>2018</b> , 4, 11	51.1	76
154 153	Cryoglobulinaemia. <i>Nature Reviews Disease Primers</i> , <b>2018</b> , 4, 11  Can type C hepatitis infection be complicated by malignant lymphoma?. <i>Lancet, The</i> , <b>1995</b> , 346, 1426-7		76 74
			<u> </u>
153	Can type C hepatitis infection be complicated by malignant lymphoma?. <i>Lancet, The</i> , <b>1995</b> , 346, 1426-7		74
153 152	Can type C hepatitis infection be complicated by malignant lymphoma?. <i>Lancet, The</i> , <b>1995</b> , 346, 1426-7  HCV and lymphoproliferation. <i>Clinical and Developmental Immunology</i> , <b>2012</b> , 2012, 980942  Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in	40	74
153 152 151	Can type C hepatitis infection be complicated by malignant lymphoma?. <i>Lancet, The</i> , <b>1995</b> , 346, 1426-7  HCV and lymphoproliferation. <i>Clinical and Developmental Immunology</i> , <b>2012</b> , 2012, 980942  Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. <i>Journal of Medical Virology</i> , <b>1995</b> , 47, 58-64  Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. <i>European Journal</i>	40	<ul><li>74</li><li>73</li><li>73</li></ul>
153 152 151 150	Can type C hepatitis infection be complicated by malignant lymphoma?. <i>Lancet, The</i> , <b>1995</b> , 346, 1426-7  HCV and lymphoproliferation. <i>Clinical and Developmental Immunology</i> , <b>2012</b> , 2012, 980942  Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. <i>Journal of Medical Virology</i> , <b>1995</b> , 47, 58-64  Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. <i>European Journal of Clinical Investigation</i> , <b>1993</b> , 23, 851-5  Hepatitis C virus infection in non-Hodgkinß B-cell lymphoma complicating mixed	40 19.7 4.6	74 73 73 72
153 152 151 150	Can type C hepatitis infection be complicated by malignant lymphoma?. <i>Lancet, The</i> , <b>1995</b> , 346, 1426-7  HCV and lymphoproliferation. <i>Clinical and Developmental Immunology</i> , <b>2012</b> , 2012, 980942  Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. <i>Journal of Medical Virology</i> , <b>1995</b> , 47, 58-64  Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. <i>European Journal of Clinical Investigation</i> , <b>1993</b> , 23, 851-5  Hepatitis C virus infection in non-Hodgkinß B-cell lymphoma complicating mixed cryoglobulinaemia. <i>European Journal of Clinical Investigation</i> , <b>1994</b> , 24, 781-4  International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A	40 19.7 4.6 4.6	74 73 73 72 71

145	Hepatitis C virus lymphotropism: lessons from a decade of studies. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39 Suppl 1, S38-45	3.3	64	
144	Relation between infection and autoimmunity in mixed cryoglobulinemia. <i>Current Opinion in Rheumatology</i> , <b>2000</b> , 12, 53-60	5.3	63	
143	Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. <i>Expert Review of Clinical Immunology</i> , <b>2015</b> , 11, 15-31	5.1	62	
142	Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. <i>Journal of Medical Virology</i> , <b>1997</b> , 51, 313-318	19.7	62	
141	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1282-1299	13.4	58	
140	Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. <i>British Journal of Rheumatology</i> , <b>1997</b> , 36, 360-5		58	
139	HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39 Suppl 1, S55-60	3.3	58	
138	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , <b>2014</b> , 53, 2209-1	<b>3</b> 3.9	55	
137	A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 714-9	13.6	55	
136	Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 833-7	3.3	54	
135	Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. <i>Journal of Viral Hepatitis</i> , <b>2006</b> , 13, 402-8	3.4	54	
134	Extrahepatic manifestations of hepatitis C virus infection. <i>Clinics in Liver Disease</i> , <b>2008</b> , 12, 611-36, ix	4.6	52	
133	Cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus. <i>American Journal of Nephrology</i> , <b>1993</b> , 13, 300-4	4.6	52	
132	B-cells and mixed cryoglobulinemia. <i>Autoimmunity Reviews</i> , <b>2007</b> , 7, 114-20	13.6	51	
131	Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fclreceptors. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 1446-51		50	
130	Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. <i>Translational Research</i> , <b>1999</b> , 134, 68-73		46	
129	Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. <i>Blood</i> , <b>1993</b> , 82, 3701-4	2.2	46	
128	Mixed cryoglobulinemia as a possible preneoplastic disorder. <i>Arthritis and Rheumatism</i> , <b>1995</b> , 38, 1859-	60	45	

127	Erectile dysfunction and hepatitis C virus infection. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 288, 698-9	27.4	45
126	Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. <i>Genes and Immunity</i> , <b>2014</b> , 15, 500-5	4.4	43
125	Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 889-96	13.6	43
124	Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 840-3	3.3	41
123	Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases. <i>PLoS ONE</i> , <b>2015</b> , 10, e0117420	3.7	40
122	"Inapparent" hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease. <i>Hepatology</i> , <b>1994</b> , 19, 577-82	11.2	39
121	Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study. <i>Current Drug Targets</i> , <b>2017</b> , 18, 772-	785	39
120	Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 780-4	3.3	39
119	Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease. <i>Journal of Internal Medicine</i> , <b>1994</b> , 236, 31-6	10.8	38
118	The hepatitis C virus infection as a systemic disease. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7 Suppl 3, S201-8	3.7	37
117	Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. <i>Archives of Virology</i> , <b>1997</b> , 142, 535-44	2.6	37
116	Thyroid cancer in HCV-related mixed cryoglobulinemia patients. <i>Clinical and Experimental Rheumatology</i> , <b>2002</b> , 20, 693-6	2.2	36
115	Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemia. <i>PLoS ONE</i> , <b>2013</b> , 8, e62965	3.7	35
114	Non-Hodgkinß lymphoma: possible role of hepatitis C virus. <i>JAMA - Journal of the American Medical Association</i> , <b>1994</b> , 272, 355-6	27.4	35
113	Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. <i>Hepatology</i> , <b>2006</b> , 43, 1166-7; author reply 1167-8	11.2	34
112	Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. <i>Blood</i> , <b>1993</b> , 81, 1132-6	2.2	34
111	Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. <i>Journal of Rheumatology</i> , <b>1996</b> , 23, 1641-3	4.1	34
110	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , <b>2017</b> , 12 e0172159	3.7	31

109	Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. <i>Clinical and Experimental Rheumatology</i> , <b>2011</b> , 29, 933-41	2.2	31
108	Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. <i>Journal of Autoimmunity</i> , <b>2015</b> , 63, 88-93	15.5	30
107	Hepatitis C virus infection and B-cell lymphomas. European Journal of Cancer, 1994, 30A, 1591-2	7.5	30
106	HBV and HCV chronic infection: autoimmune manifestations and lymphoproliferation. <i>Autoimmunity Reviews</i> , <b>2008</b> , 8, 107-11	13.6	29
105	Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients. <i>Infection</i> , <b>1993</b> , 21, 93-7	5.8	29
104	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , <b>2017</b> , 12, e018	53728	28
103	Chronic hepatitis C and B-cell non-Hodgkinß lymphoma. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>1996</b> , 89, 117-22	2.7	26
102	HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39 Suppl 1, S107-11	3.3	26
101	Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. Journal of Hepatology, <b>2008</b> , 49, 170-4	13.4	25
100	Elevated Serum Levels of Osteopontin in HCV-Associated Lymphoproliferative Disorders. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 1192-4	4.6	25
99	HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. <i>Clinical and Experimental Rheumatology</i> , <b>2003</b> , 21, S78-84	2.2	25
98	Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, S48-52	2.2	25
97	Free light chains: Eclectic multipurpose biomarker. <i>Journal of Immunological Methods</i> , <b>2017</b> , 451, 11-19	2.5	24
96	Polymyositis, lung fibrosis, and cranial neuropathy in a patient with hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , <b>1996</b> , 39, 1074-5		24
95	Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. Case Reports in Immunology, 2015, 2015, 816424	1.9	23
94	Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?. <i>Liver International</i> , <b>2018</b> , 38, 2190-2198	7.9	23
93	Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool?. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, 863-6	3.3	23
92	Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. <i>Blood</i> , <b>2008</b> , 111, 2943-5	2.2	23

91	Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases. <i>Clinical and Experimental Rheumatology</i> , <b>1997</b> , 15, 711-2	2.2	22
90	Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia?. <i>Blood</i> , <b>2008</b> , 112, 4353-4	2.2	20
89	Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study. <i>European Journal of Pharmacology</i> , <b>2017</b> , 806, 105-	-1503	19
88	Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis. <i>Liver International</i> , <b>2019</b> , 39, 628-632	7.9	19
87	Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 811-817	3.4	19
86	Hepatitis C Virus, B-Cell Disorders, and Non-Hodgkinß Lymphoma349-368		19
85	Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients subgroups. <i>Journal of Autoimmunity</i> , <b>2021</b> , 125, 102744	15.5	19
84	Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , <b>2017</b> , 66, 1814-1825	11.2	18
83	Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 440-450	6.1	17
82	Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39 Suppl 1, S129-33	3.3	17
81	Involvement of PI3K in HCV-related lymphoproliferative disorders. <i>Journal of Cellular Physiology</i> , <b>2008</b> , 214, 396-404	7	17
80	Role of the HLA class II: HCV-related disorders. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1107, 308-18	6.5	16
79	Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. <i>Oncology Reports</i> , <b>2006</b> , 15, 1305-8	3.5	16
78	Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, e107-14	3.4	15
77	Could HGV infection be implicated in lymphomagenesis?. British Journal of Haematology, 1997, 98, 778-	94.5	15
76	HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. <i>Oncotarget</i> , <b>2016</b> , 7, 37487-37497	3.3	15
75	Hepatitis C virus core protein expression in human B-cell lines does not significantly modify main proliferative and apoptosis pathways. <i>Journal of General Virology</i> , <b>2002</b> , 83, 1665-1671	4.9	15
74	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 731-741	3.3	14

73	Autoimmunity and lymphoproliferation markers in naMe HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 927-33	3.3	14
72	Hepatitis-C-virus infection and cancer. <i>International Journal of Cancer</i> , <b>1997</b> , 71, 1113-5	7.5	14
71	Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame?. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 8910-5	5.6	14
70	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 427-434	18.8	13
69	Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment. <i>Liver International</i> , <b>2015</b> , 35, 2100-7	7.9	13
68	From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease, <b>2016</b> , 48, 995-1005	3.3	12
67	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, 21	8.5	12
66	The liver-cytokine-brain circuit in interferon-based treatment of patients with chronic viral hepatitis. <i>Journal of Viral Hepatitis</i> , <b>2011</b> , 18, 525-32	3.4	12
65	Lymphotropic virus infection of peripheral blood mononuclear cells in B-cell non-Hodgkinß lymphoma. <i>Acta Haematologica</i> , <b>1997</b> , 98, 89-94	2.7	12
64	Hepatitis C virus core protein enhances B lymphocyte proliferation. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39 Suppl 1, S72-5	3.3	12
63	Treatment of HCV-Related Mixed Cryoglobulinemia. Current Drug Targets, 2017, 18, 794-802	3	12
62	Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. <i>Clinical Rheumatology</i> , <b>2013</b> , 32, 1147-54	3.9	11
61	IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1233-1239	3.3	11
60	Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 158	8.5	11
59	Hepatitis C virus in mixed cryoglobulinemia and B cell lymphoma. <i>Clinical and Experimental Rheumatology</i> , <b>1994</b> , 12, 89-90	2.2	11
58	Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. <i>BioMed Research International</i> , <b>2014</b> , 2014, 710642	3	10
57	Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 3013-9	5.6	10
56	MicroRNA expression in hepatitis C virus-related malignancies: A brief review. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 8562-8	5.6	9

## (1995-2007)

55	Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2007</b> , 14, 22-8	3.4	9	
54	Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 245-249	2.5	9	
53	Monoclonal gammopathy in patients with chronic hepatitis C virus infection. <i>Blood</i> , <b>1996</b> , 88, 1122	2.2	9	
52	Etiopathogenetic role of hepatitis C virus in mixed cryoglobulinemia, chronic liver diseases and lymphomas. <i>Clinical and Experimental Rheumatology</i> , <b>1995</b> , 13 Suppl 13, S135-40	2.2	9	
51	Reply. <i>Hepatology</i> , <b>2017</b> , 65, 1771-1772	11.2	8	
50	Effect of chronic hepatitis C virus infection on inflammatory lipid mediators. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39 Suppl 1, S76-82	3.3	8	
49	Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma. <i>Clinical and Experimental Hepatology</i> , <b>2018</b> , 4, 197-200	2.2	8	
48	Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 938-943	3.3	7	
47	Hepatitis C-associated B-cell non-Hodgkin lymphomas: the emerging role of miRNA-26b. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 1362-3	13.4	7	
46	JH6 gene usage among HCV-associated MALT lymphomas harboring t(14;18) translocation. <i>Journal of Immunology</i> , <b>2005</b> , 174, 3839; author reply 3839	5.3	7	
45	Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar). <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 149-156	3.7	7	
44	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 (years with HCV genotype 1 cirrhosis. <i>Infection</i> , <b>2018</b> , 46, 607-615	5.8	7	
43	Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies. <i>Hepatology International</i> , <b>2015</b> , 9, 586-93	8.8	6	
42	Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 44	5.7	6	
41	High circulating chemokines (C-X-C motif) ligand 9, and (C-X-C motif) ligand 11, in hepatitis C-associated cryoglobulinemia. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2013</b> , 26, 49-57	3	6	
40	Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases. <i>Oncotarget</i> , <b>2017</b> , 8, 71528-71535	3.3	6	
39	Expert opinion on managing chronic HCV in patients with mixed cryoglobulinaemia vasculitis. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 1-9	1.6	6	
38	Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. <i>Clinical and Experimental Rheumatology</i> , <b>1995</b> , 13 Suppl 13, S33-7	2.2	6	

37	Hepatitis C virus and mixed cryoglobulinaemia. <i>Rheumatology</i> , <b>1994</b> , 33, 301	3.9	5
36	Latent hepatitis B virus (HBV) infection in systemic necrotizing vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>1991</b> , 9, 23-8	2.2	5
35	HCV-Related Rheumatic Manifestations and Therapeutic Strategies. Current Drug Targets, 2017, 18, 803	3- <b>§</b> 10	5
34	Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection. <i>Acta Biomedica</i> , <b>2018</b> , 89, 321-3	3312	5
33	Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia. <i>Journal of Immunological Methods</i> , <b>2020</b> , 476, 112687	2.5	5
32	Real life experiences in HCV management in 2018. Expert Review of Anti-Infective Therapy, 2019, 17, 11	7-51.328	5
31	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , <b>2021</b> , 27, 4245-4252	3.3	5
30	Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice. <i>Liver International</i> , <b>2018</b> , 38, 183	7.9	4
29	Reducing the price of new hepatitis C drugs in the Tuscany region of Italy. <i>BMJ, The</i> , <b>2015</b> , 350, h3363	5.9	4
28	Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC). <i>Viruses</i> , <b>2021</b> , 13,	6.2	4
27	A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders. <i>Genes and Immunity</i> , <b>2020</b> , 21, 131-135	4.4	3
26	HCV infection, malignancy, and liver transplantation. <i>Transplantation Proceedings</i> , <b>2003</b> , 35, 1032-3	1.1	3
25	A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort <i>Hepatology</i> , <b>2021</b> ,	11.2	3
24	Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	3
23	Role of Notch Receptors in Hematologic Malignancies. <i>Cells</i> , <b>2020</b> , 10,	7.9	3
22	Impact of direct acting antivirals on hepatitis C virus-related cryoglobulinemic syndrome. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67, 218-226	3	3
21	Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis. <i>Hepatology</i> , <b>2021</b> , 74, 116	34 <sup>1</sup> 177:	33
20	A randomized, controlled study of peginterferon lambda-1a/ribavirin daclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , <b>2016</b> , 5, 1365		3

19	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 612-619	3.3	3
18	Current and future challenges in HCV: insights from an Italian experts panel. <i>Infection</i> , <b>2018</b> , 46, 147-16	535.8	3
17	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and	4.8	3
16	Italian society of nephrology (SIN). <i>Journal of Nephrology</i> , <b>2018</b> , 31, 685-712  Lack of preferential localization of tumoral mass in B-cell non-Hodgkinß lymphoma associated with hepatitis C virus infection. <i>Blood</i> , <b>1997</b> , 89, 3066-8	2.2	3
15	SARS-CoV-2 was already circulating in Italy, in early December 2019. European Review for Medical and Pharmacological Sciences, <b>2021</b> , 25, 3342-3349	2.9	3
14	The Expanding Spectrum of Clinical Features in HCV-Related Mixed Cryoglobulinemia <b>2012</b> , 155-162		2
13	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and	3.7	2
12	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and	3.3	2
11	Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 661-666	2.5	1
10	REPLY. <i>Hepatology</i> , <b>2021</b> , 74, 2910	11.2	1
10	REPLY. <i>Hepatology</i> , <b>2021</b> , 74, 2910  PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. <i>Liver International</i> , <b>2021</b> , 41, 133-149	7.9	1
	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. <i>Liver</i>		
9	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. <i>Liver International</i> , <b>2021</b> , 41, 133-149  Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease	7.9	1
9	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. <i>Liver International</i> , <b>2021</b> , 41, 133-149  Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. <i>Rheumatology</i> , <b>2021</b> , 60, 4418-4427  Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and	7·9 3·9 3·9	1
9 8 7	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. <i>Liver International</i> , <b>2021</b> , 41, 133-149  Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. <i>Rheumatology</i> , <b>2021</b> , 60, 4418-4427  Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis. <i>Clinical Rheumatology</i> , <b>2021</b> , 1  Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with	7·9 3·9 3·9	1 1
9 8 7 6	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. <i>Liver International</i> , 2021, 41, 133-149  Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. <i>Rheumatology</i> , 2021, 60, 4418-4427  Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis. <i>Clinical Rheumatology</i> , 2021, 1  Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life. <i>Autoimmunity Reviews</i> , 2021, 102923  Direct antiviral agents for treatment-naße patients with genotype 1 hepatitis C: A statistical model	7·9 3·9 3·9	1 1
9 8 7 6	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. <i>Liver International</i> , <b>2021</b> , 41, 133-149  Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. <i>Rheumatology</i> , <b>2021</b> , 60, 4418-4427  Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis. <i>Clinical Rheumatology</i> , <b>2021</b> , 1  Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life. <i>Autoimmunity Reviews</i> , <b>2021</b> , 102923  Direct antiviral agents for treatment-naße patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 98	7·9 3·9 3·9	1 1

1 Reply.. Hepatology, 2022,

11.2